The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Penny stocks are a tripwire for mayhem. They can easily blow up your portfolio....
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular thera...
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th....
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular thera...
Longeveron Inc (NASDAQ: LGVN) rallied another 50% on Thursday as investors continued to celebrate the positive update of its Lomecel-B study. Why is it significant for Longeveron stock?...
Longeveron (NASDAQ: LGVN ) stock continues to rally on Thursday as investors celebrate positive trial news from the clinical-stage biotechnology company. The big news that boosted shares of LGVN stoc...
The clinical-stage biotech market is as vast as it is complicated. Companies operating in this space are wide-ranging in the illnesses they look to treat....
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms....
MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agin...